Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
18 10 2021
Historique:
received: 07 08 2020
pubmed: 21 2 2021
medline: 15 2 2022
entrez: 20 2 2021
Statut: ppublish

Résumé

Ileal pouch-anal anastomosis (IPAA) is the standard of care after total proctocolectomy for ulcerative colitis (UC). However, inflammation often develops in the pouch, leading to acute or recurrent/chronic pouchitis (R/CP). MicroRNAs (miRNA) are used as accurate diagnostic and predictive biomarkers in many human diseases, including inflammatory bowel diseases. Therefore, we aimed to identify an miRNA-based biomarker to predict the occurrence of R/CP in patients with UC after colectomy and IPAA. We conducted a retrospective study in 3 tertiary centers in France. We included patients with UC who had undergone IPAA with or without subsequent R/CP. Paraffin-embedded biopsies collected from the terminal ileum during the proctocolectomy procedure were used for microarray analysis of miRNA expression profiles. Deep neural network-based classifiers were used to identify biomarkers predicting R/CP using miRNA expression and relevant biological and clinical factors in a discovery cohort of 29 patients. The classification algorithm was tested in an independent validation cohort of 28 patients. A combination of 11 miRNA expression profiles and 3 biological/clinical factors predicted the outcome of R/CP with 88% accuracy (area under the curve = 0.94) in the discovery cohort. The performance of the classification algorithm was confirmed in the validation cohort with 88% accuracy (area under the curve = 0.90). Apoptosis, cytoskeletal regulation by Rho GTPase, and fibroblast growth factor signaling were the most dysregulated targets of the 11 selected miRNAs. We developed and validated a computational miRNA-based algorithm for accurately predicting R/CP in patients with UC after IPAA.

Sections du résumé

BACKGROUND
Ileal pouch-anal anastomosis (IPAA) is the standard of care after total proctocolectomy for ulcerative colitis (UC). However, inflammation often develops in the pouch, leading to acute or recurrent/chronic pouchitis (R/CP). MicroRNAs (miRNA) are used as accurate diagnostic and predictive biomarkers in many human diseases, including inflammatory bowel diseases. Therefore, we aimed to identify an miRNA-based biomarker to predict the occurrence of R/CP in patients with UC after colectomy and IPAA.
METHODS
We conducted a retrospective study in 3 tertiary centers in France. We included patients with UC who had undergone IPAA with or without subsequent R/CP. Paraffin-embedded biopsies collected from the terminal ileum during the proctocolectomy procedure were used for microarray analysis of miRNA expression profiles. Deep neural network-based classifiers were used to identify biomarkers predicting R/CP using miRNA expression and relevant biological and clinical factors in a discovery cohort of 29 patients. The classification algorithm was tested in an independent validation cohort of 28 patients.
RESULTS
A combination of 11 miRNA expression profiles and 3 biological/clinical factors predicted the outcome of R/CP with 88% accuracy (area under the curve = 0.94) in the discovery cohort. The performance of the classification algorithm was confirmed in the validation cohort with 88% accuracy (area under the curve = 0.90). Apoptosis, cytoskeletal regulation by Rho GTPase, and fibroblast growth factor signaling were the most dysregulated targets of the 11 selected miRNAs.
CONCLUSIONS
We developed and validated a computational miRNA-based algorithm for accurately predicting R/CP in patients with UC after IPAA.

Identifiants

pubmed: 33609036
pii: 6145454
doi: 10.1093/ibd/izab030
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1653-1660

Informations de copyright

© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ian Morilla (I)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.
Université Sorbonne Paris-Nord, Laboratoire d'Excellence Inflamex, Villetaneuse, France.

Mathieu Uzzan (M)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.
Département de Gastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, Clichy la Garenne, Clichy Cedex, France.

Dominique Cazals-Hatem (D)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.
Service d'anatomopathologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, Clichy la Garenne, France.

Nathalie Colnot (N)

Service d'anatomopathologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, Clichy la Garenne, France.

Yves Panis (Y)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.
Service de chirurgie colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, Clichy la Garenne, France.

Stéphane Nancey (S)

Service d'Hépato-Gastroentérologie, Hospices Civils de Lyon, Lyon, France.

Gilles Boschetti (G)

Service d'Hépato-Gastroentérologie, Hospices Civils de Lyon, Lyon, France.

Aurélien Amiot (A)

Service de Gastroentérologie, Hôpital Henri Mondor, Créteil, France.

Xavier Tréton (X)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.
Département de Gastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, Clichy la Garenne, Clichy Cedex, France.

Eric Ogier-Denis (E)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.

Fanny Daniel (F)

INSERM U1149, Université de Paris, Centre de Recherche sur l'inflammation, Team Gut Inflammation, Paris, France.
Laboratory of Excellence Labex INFLAMEX, Sorbonne Paris-Cité, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH